Discoid Lupus Erythematosus Serum

Human Discoid Lupus Erythematosus Serum for Cutaneous Lupus Research

Our Discoid Lupus Erythematosus Serum is sourced from IRB-consented donors clinically diagnosed with discoid lupus erythematosus (DLE). Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality for cytokine profiling, interferon-related analyte work, and serological studies. Research Use Only (RUO).

Cutaneous Lupus Biology and Why Serum

  • Discoid lupus erythematosus is the most common form of chronic cutaneous lupus erythematosus. It is a skin-limited autoimmune disease, and most people with DLE do not have systemic lupus erythematosus. DLE should not be treated as an SLE surrogate.
  • Lesions are well-demarcated, scaly, and often scarring, with follicular plugging and dyspigmentation; scalp involvement can produce scarring alopecia. Ultraviolet exposure is a recognized trigger.
  • Histologically the disease is an interface dermatitis with a lymphocytic infiltrate at the dermoepidermal junction and around adnexal structures, indicating a cell-mediated, skin-directed autoimmune process.
  • Serologically, DLE differs from SLE: antinuclear antibodies are frequently negative or present only at low titer, and the high-titer anti-dsDNA pattern characteristic of SLE is not a feature of skin-limited disease.
  • Type I interferon activity is well established in cutaneous lupus and is the basis for interferon-directed therapeutic interest, so interferon-regulated soluble mediators and chemokines are informative circulating analytes.
  • Serum is acellular and is the appropriate matrix for autoantibody testing, cytokine and chemokine immunoassays, and proteomic discovery. It does not support flow cytometry or other cell-based readouts.

Donor Stratification Available

  • Localized versus generalized (disseminated) discoid disease
  • Lesion distribution: head and neck only versus involvement below the neck; scalp involvement with scarring alopecia
  • Antinuclear antibody status and titer where documented
  • Absence versus presence of concurrent systemic lupus criteria, allowing skin-limited cohorts to be requested specifically
  • Treatment status: topical or intralesional corticosteroid, antimalarial therapy, systemic immunosuppressant, or untreated
  • Disease duration, Fitzpatrick skin type where available, plus age, sex, and self-reported race/ethnicity
  • Matched healthy controls available

Product Features

  • Collected from clinically confirmed DLE donors
  • Processed and frozen within 24 hours of collection
  • Research Use Only (RUO)
  • Standard and custom aliquot volumes available
  • IRB-approved protocols with documented electronic consent

De-identified Donor Data

  • Diagnosis confirmation
  • Age, sex assigned at birth, and ethnicity
  • Donor-reported allergy and infectious disease history
  • Lesion distribution, serology, and treatment history where available
  • Additional DLE-specific metadata on request

Applications

  • Autoantibody detection and ANA assay development in skin-limited lupus
  • Serum cytokine and chemokine profiling
  • Interferon-regulated soluble analyte research
  • Serum proteomics for cutaneous lupus biomarker discovery
  • Comparative serology against systemic lupus and other cutaneous lupus subtypes
  • Photosensitivity and UV response biomarker studies
  • Therapeutic candidate screening and treatment-response research
  • Disease-state matrix for immunoassay validation

Other Discoid Lupus Erythematosus Specimen Types

Compliance and Quality Assurance

  • IRB-approved and HIPAA-compliant protocols
  • Electronic informed consent with 21 CFR Part 11-compliant e-signatures
  • Documentation support available for regulatory review

Ordering & Customization

Discoid Lupus Erythematosus Serum is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse all matrices and disease states, visit our human serum page.

Protocols & Documentation

  • Serum Isolation

    Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

Serum

Frequently Asked Questions

Showing 1–12 of 24 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom Serum cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information